PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D
PharmaTher Establishes PERSONALIZ3D to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
PharmaTher Collaborates with Craft Health to Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
PharmaTher Enters into Collaboration Agreement for KetaMist to Advance Needle-Free Ketamine Treatment Toward FDA Approval
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
PharmaTher Introduces PatchPrint With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
